OKG 0303
Alternative Names: OKG-0303Latest Information Update: 15 Jan 2024
Price :
$50 *
At a glance
- Originator Okogen
- Class Antibacterials; Antineoplastics; Antivirals; Decongestants; Eye disorder therapies; Ribonucleases
- Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors; Ribonuclease replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Infectious conjunctivitis
Most Recent Events
- 31 Oct 2023 Phase-II clinical trials in Infectious conjunctivitis in India (Ophthalmic)
- 10 Oct 2023 Clinical trials in Infectious conjunctivitis (Ophthalmic) before October 2023 (Okogen pipeline, October 2023)
- 10 Oct 2023 Okogen plans a phase IIb trial for Infectious conjunctivitis (Ophthalmic) (Okogen pipeline, October 2023)